Accolade (Nasdaq: ACCD), a US-based healthcare company, announced on Thursday that it has named Elizabeth Nabel, MD and Jeff Brodsky as its new directors.
Dr Nabel is the executive vice president for strategy at ModeX Therapeutics. She served for eleven years as the president of Brigham and Women's Hospital. She directed the National Heart, Lung, and Blood Institute of the National Institutes of Health and also serves on the boards of directors of Moderna, a pharmaceutical company, and Medtronic, a medical device company.
Brodsky is the vice chairman at Morgan Stanley and member of its operating committee. He has over 30 years of experience at Morgan Stanley and held various leadership roles across the human resources function. He also serves on the Safe Horizon board of directors and is an executive in residence at the University of Michigan's Ross School of Business, where he earlier served on the advisory board.
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions